文献速递肝病消化道肿瘤与早癌

罕见ATG7基因变异使患者易患重度脂肪性肝病

Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
PubMed 文献 · J Hepatol · 2022-04-09

该研究对301例非酒精性脂肪性肝病(NAFLD)伴进展期纤维化或肝细胞癌患者行全外显子测序,发现ATG7功能缺失罕见变异富集,UK Biobank中ATG7功能缺失变异增加肝硬化和肝细胞癌风险。

要点

  • 重度NAFLD患者中ATG7 p.P426L变异富集(OR 5.26,95%CI 2.1-12.6,p=0.003)。
  • UK Biobank中ATG7功能缺失变异增加肝硬化(OR 3.30,95%CI 1.1-7.5)和肝细胞癌(OR 12.30,95%CI 2.6-36)风险,p均<0.001。
  • p.V471A变异与重度NAFLD相关(OR 1.7,95%CI 1.2-2.5,p=0.003),并易患肝细胞气球样变(p=0.007)进展为纤维化。

核心结论

  • 研究鉴定出罕见及低频ATG7功能缺失变异通过损害自噬、促进气球样变和炎症来推动NAFLD进展。

研究设计与样本

  • 对301例NAFLD伴进展期纤维化或肝细胞癌个体行全外显子测序,并与一般人群比较可能致病罕见变异的富集,随后在基因水平验证。
  • 肝活检队列(n=2,268)、UK Biobank队列和肝脏转录组队列(n=125)用于验证。

主要发现

  • 重度NAFLD患者中p.P426L变异(rs143545741 C>T)富集(OR 5.26,95%CI 2.1-12.6;p=0.003),该变异被鉴定为功能缺失。
  • 影响催化域的罕见变异富集(OR 13.9;95%CI 1.9-612;p=0.002)。
  • UK Biobank中ATG7功能缺失变异增加肝硬化风险(OR 3.30;95%CI 1.1-7.5)和肝细胞癌风险(OR 12.30;95%CI 2.6-36),p均<0.001。
  • 低频功能缺失p.V471A变异(rs36117895 T>C)与临床队列重度NAFLD相关(OR 1.7;95%CI 1.2-2.5;p=0.003),易患肝细胞气球样变(p=0.007)并进展为纤维化(肝活检队列n=2,268),在UK Biobank中与肝损伤相关(天冬氨酸氨基转移酶水平,p<0.001),在重度肥胖个体中与肝细胞癌相关(p=0.009)。

关键数值与推荐

  • p.P426L变异与重度NAFLD的OR 5.26(95%CI 2.1-12.6;p=0.003)。
  • 催化域罕见变异与重度NAFLD的OR 13.9(95%CI 1.9-612;p=0.002)。
  • UK Biobank中ATG7功能缺失变异与肝硬化的OR 3.30(95%CI 1.1-7.5),与肝细胞癌的OR 12.30(95%CI 2.6-36),p均<0.001。
  • p.V471A变异与重度NAFLD的OR 1.7(95%CI 1.2-2.5;p=0.003)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci that contribute to severe NAFLD by examining rare variants. METHODS: We performed whole-exome sequencing in individuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n = 301) and examined the enrichment of likely pathogenic rare variants vs. the general population. This was followed by validation at the gene level. RESULTS: In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; odds ratio [OR] 5.26, 95% CI 2.1-12.6; p = 0.003) of autophagy-related 7 (ATG7), which we characterized as a loss-of-function, vs. the general population, and an enrichment in rare variants affecting the catalytic domain (OR 13.9; 95% CI 1.9-612; p = 0.002). In the UK Biobank cohort, loss-of-function ATG7 variants increased the risk of cirrhosis and hepatocellular carcinoma (OR 3.30; 95% CI 1.1-7.5 and OR 12.30, 95% CI 2.6-36, respectively; p <0.001 for both). The low-frequency loss-of-function p.V471A variant (rs36117895 T>C) was also associated with severe NAFLD in the clinical cohort (OR 1.7; 95% CI 1.2-2.5; p = 0.003), predisposed to hepatocellular ballooning (p = 0.007) evolving to fibrosis in the Liver biopsy cohort (n = 2,268), and was associated with liver injury in the UK Biobank (aspartate aminotransferase levels, p <0.001), with a larger effect in severely obese individuals in whom it was linked to hepatocellular carcinoma (p = 0.009). ATG7 protein localized to periportal hepatocytes, particularly in the presence of ballooning. In the Liver Transcriptomic cohort (n = 125), ATG7 expression correlated with suppression of the TNFα pathway, which was conversely upregulated in p.V471A carriers. CONCLUSIONS: We identified rare and low-frequency ATG7 loss-of-function variants that promote NAFLD progression by impairing autophagy and facilitating ballooning and inflammation. LAY SUMMARY: We found that rare mutations in a gene called autophagy-related 7 (ATG7) increase the risk of developing severe liver disease in individuals with dysmetabolism. These mutations cause an alteration in protein function and impairment of self-renewal of cellular content, leading to liver damage and inflammation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Baselli GA, Jamialahmadi O, Pelusi S, et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol. 2022. PMID: 35405176. doi:10.1016/j.jhep.2022.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。